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Receptor tyrosine kinase inhibitorsVascular endothelial growth factor (VEGF) is an important mediator of angiogenesis. Here we have used a
novel stoichiometric protein-labeling method to generate a fluorescent variant of VEGF (VEGF165a-TMR)
labeled on a single cysteine within each protomer of the antiparallel VEGF homodimer. VEGF165a-TMR
has then been used in conjunction with full length VEGFR2, tagged with the bioluminescent protein
NanoLuc, to undertake a real time quantitative evaluation of VEGFR2 binding characteristics in living cells
using bioluminescence resonance energy transfer (BRET). This provided quantitative information on
VEGF-VEGFR2 interactions. At longer incubation times, VEGFR2 is internalized by VEGF165a-TMR into
intracellular endosomes. This internalization can be prevented by the receptor tyrosine kinase inhibitors
(RTKIs) cediranib, sorafenib, pazopanib or vandetanib. In the absence of RTKIs, the BRET signal is
decreased over time as a consequence of the dissociation of agonist from the receptor in intracellular
endosomes and recycling of VEGFR2 back to the plasma membrane.
 2017 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Vascular endothelial growth factor A (VEGF-A) is an important
mediator of tumour-induced angiogenesis [1–4]. Multiple isoforms
of VEGF-A exist as a consequence of alternative exon splicing
[1,5,6]. Furthermore, alternative splicing in exon 8 of the VEGF-A
gene can generate additional isoforms with different pharmacolog-
ical properties [5,6]. For example, VEGF165b has been reported to
be a partial agonist at VEGFR2 [7–10] and an inhibitor of angiogen-
esis in vivo [5].VEGF family members bind to three VEGF receptors (VEGFR1,
VEGFR2 and VEGFR3) with differing selectivity profiles [1,2].
VEGFR2 is the major regulator of VEGF-driven responses in vascu-
lar endothelial cells including permeability, proliferation, invasion,
migration and angiogenesis [1,2]. The binding of VEGF to VEGFRs
leads to a change in conformation of their intracellular domains
and auto- or trans-phosphorylation of specific tyrosine residues
of the receptor dimer resulting in the activation of different intra-
cellular signalling cascades [11–14]. These signalling pathways are
relatively well understood with tyrosine residues Y1175 and
Y1214 in the human VEGFR2 being two important auto-
phosphorylation sites activated by VEGF binding and tyrosine
kinase activation. Phosphorylation of these specific residues cre-
ates binding sites for key intracellular signalling proteins such as
Grb2, PLCc and SHC [14–16].eceptor
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dimers (e.g. the insulin receptor) or dimerize upon ligand binding
[16–18]. Detailed biophysical studies with purified recombinant
receptors and receptor domains have provided some insights into
the requirement of ligand binding for the formation of VEGFR2
receptor dimers [11,12]. Ligand binding to VEGFR2 requires Ig-
like domains D2 and D3 in the extracellular portion of the receptor
[11,19,20]. Structural analysis [21,22] and X-ray crystallography
[23–25] has suggested that ligand binding to VEGFR-2 promotes
receptor dimerization. Detailed analysis of the interaction of VEGF
with purified recombinant D2-D3 domains of VEGFR2 confirmed
that ligand/receptor complexes consisted of two receptor mole-
cules and one VEGF ligand dimer. Furthermore, in the absence of
ligand, these D2-D3 recombinant domains are monomeric [23].
Although detailed quantitative characterisation of the interac-
tions of RTK ligands with full-length target receptors in living cells
is largely lacking, approaches to achieve this have been suggested
from research into other cell surface receptor families. For exam-
ple, significant advances in our knowledge of G protein-coupled
receptors (GPCRs) have come from quantitative analysis of
ligand-receptor interactions in living cells [26–28]. Furthermore,
the recent development of new fluorescent ligand technologies
has provided significant advances in our ability to unravel the com-
plexities of these interactions [27,29]. We have recently developed
a novel and quantitative approach to monitor ligand-receptor
interactions in living cells based on bioluminescence resonance
energy transfer (BRET) [30]. This approach monitors energy trans-
fer from a new bright luminescent protein (NanoLuc luciferase)
genetically fused to the N-terminus of a GPCR to a red or green flu-
orescent ligand specifically bound to the target receptor.
Here we have developed a method for stoichiometric labeling of
VEGF165a at a single N-terminal cysteine, which retains its full ago-
nist activity. This tetramethyl-rhodamine (TMR) labeled VEGF
(VEGF165a-TMR) has been used in conjunction with VEGFR2 genet-
ically fused to NanoLuc to provide detailed quantitative informa-
tion on ligand binding characteristics, the effect of receptor
tyrosine kinase inhibitors and the internalization of agonist-
receptor complexes in living cells.2. Materials and methods
2.1. Materials
All recombinant human VEGF ligand isoforms were purchased
from R&D Systems (Abingdon, UK). Cediranib, pazopanib, sorafenib
and vandetanib were supplied by Sequoia Research Products
(Pangbourne, UK). ONE-GloTM luciferase and HaloTag ligands were
purchased from Promega Corporation (Wisconsin, USA).
2.2. Construct for producing labeled VEGF165a
The VEGF165a cDNA was synthetically generated by Gene
Dynamics LLC (Oregon, USA) and sub cloned into a modified
pFN21 HaloTag CMV Flexi Vector (G2821; Promega Corporation,
USA) containing an IL6 secretion signal. The linker sequence sepa-
rating the two fusion partners was replaced with a linker encoding
EPTTEDLYFQCDN.
2.3. Constructs for VEGFR2
VEGFR2 was subcloned from a plasmid obtained from Origene
(NM_002253; Maryland, USA). For N terminal NanoLuc tagged con-
structs, VEGFR2 was cloned into a pF-sNnK CMV/neo vector
(N1321; Promega Corporation, USA) encoding a fusion of the signal
peptide sequence of IL-6 onto the N terminus of NanoLuc (NLuc).Please cite this article in press as: L.E. Kilpatrick et al., Real-time analysis of the
tyrosine kinase inhibitors and fate of internalized agonist-receptor complexesThis resulted in open reading frames (ORFs) which encoded NLuc
fused via a Gly-Ser-Ser-Gly(AIA) linker to the N terminus of
VEGFR2 (termed NLuc VEGFR2). For N terminal HaloTag constructs,
VEGFR2 cDNA was cloned into a pFN21A CMV/neo flexi vector
encoding a fusion of the signal peptide sequence of IL-6 onto the
N terminus of HaloTag. The resultant ORFs encoded HaloTag fused
to the N terminus of VEGFR2 via a EPTTEDLYFQSDN(AIA) linker
(Halo VEGFR2). C terminal HaloTag VEGFR2 was created by cloning
VEGFR2 cDNA into a pFC27K CMV/neo flexi vector (G8431; Pro-
mega Corporation, USA). This fused HaloTag onto the C terminus
of VEGFR2 via a (VSL)EPTTEDLYFQSDND linker, resulting in
VEGFR2-HaloTag (VEGFR2-Halo).2.4. Synthesis and purification of VEGF165a-TMR
VEGF165a was transiently expressed as a secreted HaloTag
fusion protein in 1 L of HEK293T cells and purified using the Halo-
Tag mammalian protein detection and purification system (G6795;
Promega Corporation, USA) following the manufacturer’s recom-
mendations. Briefly, after 72 h of expression, the media containing
the secreted fusion protein was collected and applied onto 1.8 ml
of pre-equilibrated HaloLink beads. Binding to the beads was con-
ducted at 4 C over night (16–18 h) with constant end over end
rotation. Following three washes of the beads, each for 10 min,
VEGF165a was released from the beads by proteolytic cleavage
using 700 units of HaloTEV in the presence of 100 mM TCEP
(Sigma-Aldrich, USA). For the generation of a labeled VEGF165a,
the HaloTEV proteolytic release was done in the presence of
100 mM TCEP and 4 molar excess of 6-TMR-PEG-CBT [31] over
the expressed fusion protein. To determine the amount of 6-
TMR-PEG-CBT (moles) required for the proteolytic/labeling reac-
tion, the amount of expressed HaloTag:VEGF165a (moles) was cal-
culated as described previously [33]. The proteolytic/labeling
reaction was conducted at 4 C over night (16–18 h) with constant
mixing. This step generated VEGF165a with an N-terminal cysteine
that served as single point of conjugation with 6-TMR-PEG-CBT.
The purified labeled VEGF165a was dialyzed for 24 h (50 mM
HEPES, 150 mM NaCl; Sigma-Aldrich, USA) to remove the unconju-
gated 6-TMR-PEG-CBT and TCEP. The yield from 1L commonly ran-
ged between 0.5 and 1 mg. The purified protein was stored without
any further concentration in the presence of 2.5 mg/ml bovine
serum albumin (BSA; Millipore, USA; final concentration) in ali-
quots at -80 C (final concentration ranged between 80 and
300 mg/ml).2.5. Cell culture
All HEK293T cell lines were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM 6429; Sigma-Aldrich, UK) supplemented
with 10% fetal calf serum (Sigma-Aldrich, UK) at 37 C/5% CO2.
All stable and transient transfections were performed using
FuGENE HD (Promega Corporation, USA) according to the manufac-
turer’s instructions at a reagent to cDNA ratio of 3:1.2.6. Stable cell line generation and maintenance
Stable HEK293T NanoLuc VEGFR2 (NLuc-VEGFR2) and HEK293T
VEGFR2-HaloTag cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; D6429; Sigma-Aldrich, UK) supplemented with
10% fetal calf serum and incubated at 37 C/5% CO2. Cell passaging
was performed when cells reached 80% confluency using PBS (Lon-
za, Switzerland) and trypsin (0.25% w/v in versene; Lonza, Switzer-
land). We confirmed that these cell lines were mycoplasma free.binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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Dimerization assay: purified VEGF165a-TMR was analysed on
SDS-PAGE in the presence and absence of 100 mM dithiothreitol
(DTT; Sigma-Aldrich, UK) and then scanned on a Typhoon 9400 flu-
orescent imager (GE Healthcare, USA), (Excitation = 532 nm;
Emission = 580 nm).
Glycosylation assay: purified VEGF165a-TMR was treated with
PNGase (Promega Corporation, USA) as recommended by the man-
ufacturer. Treated and untreated VEGF165a-TMR were analysed on
SDS-PAGE and then scanned on a Typhoon 9400 fluorescent imager
(GE Healthcare, USA), (Excitation = 532 nm; Emission = 580 nm).2.8. Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
analysis
VEGF165a-TMR and VEGF165a purified in the same manner were
suspended in 50 mM ammonium bicarbonate (0.1 mg/ml; Sigma-
Aldrich, USA) and reduced with 25 mM TCEP at 50 C for 1 h. Fol-
lowing reduction, the appropriate protease (LysC, GluC, or tryp-
sin/LysC from Promega Corporation, USA) were added to the
sample (1:20 enzyme/substrate ratio) and subjected to proteolysis
for 3 h at 37 C with shaking at 400 rpm (Eppendorf Thermomixer).
Following this step, the reaction was quenched by the addition of
formic acid (1% final concentration; Sigma-Aldrich, USA) and sub-
jected to LC-MS/MS analysis on a Q Exactive Hybrid Quadrupole-
Orbitrap Mass Spectrometer (Thermo Fisher Scientific, USA) oper-
ating with an MS resolution of 70,000.
Analysis of labeling specificity and efficiency: the mass of the
modification (i.e. the mass of the dye after covalent attachment
to an N-terminal cysteine) was determined to be 817.28 Da. MS-
product component of the Protein Prospector software (University
of California, USA) was used to calculate the mono-isotopic masses
of the modified and unmodified peptides at different charge states
(Z = 2–5 were considered; Table 1). Extracted Ion Chromatograms
were generated using Xcalibur (Thermo Fisher Scientific, USA). As
equimolar amounts of samples were loaded onto the LC-MS/MS,
labeling efficiency could also be determined by comparing the
integrated peak areas of the unmodified proteolytic peptides in
the labeled and unlabeled samples (Table 1).Table 1
LS-MS/MS profiles for (a) unlabeled and (b) labeled peptide fragments obtained followin
VEGF165a-TMR was determined by comparing the integrated peak areas of the unmodifie
LysC, GluC or Trypsin/LysC. The analysis indicated >98% labeling efficiency. (b) Observed
increase of 817 Da due to covalent attachment of the 6-TMR-PEG-CBT. *Mono-isotopic mass
[M+H] is calculated as (m/z) * z  (z  1).
(a) Unlabeled peptides
Peptide Sequence Mass/charge (m/
z)
Charge
(z)
Mass [M
+H]*
Rete
(mi
CDNAPM(Ox)
AEGGGQNHHEVVK
670.29 3 2008.86 8.06
CDNAPM(Ox)
AEGGGQNHHEVVK
670.29 3 2008.86 8.29
CDNAPMAEGGGQNHHEVVK 664.96 3 1992.87 10.4
CDNAPMAEGGGQNHHEVVK 664.96 3 1992.87 10.8
CDNAPM(Ox)AE 425.65 2 850.31 14.2
CDNAPM(Ox)AE 425.65 2 850.31 13.9
(b) Labeled peptides
Peptide Sequence Mass/Charge
(m/z)
Charge
(z)
Mass of labeled peptide
[M+H]* (A)
M
[
CDNAPM(Ox)
AEGGGQNHHEVVK
707.29 4 2826.14 2
CDNAPMAEGGGQNHHEVVK 937.38 3 2810.14 1
CDNAPM(Ox)AE 556.53 3 1667.59 8
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Solution FCS was performed essentially as described previously
[32]. Briefly, FCS was performed in Nunc Labteck 8 well chambered
coverglasses (ThermoFisher Scientific, UK) using a LSM510 NLO
Confocor3 microscope equipped with a c-Apochromat 40/1.2NA
water-immersion objective (Zeiss, Germany). The confocal volume
was placed in the solution 200 lm above the surface of the cover-
slip. Beam paths were calibrated using 20 nM Rhodamine 6G (R6G;
D = 2.8  1010 m2/s; Sigma-Aldrich, UK) prepared in high perfor-
mance liquid chromatography grade water (Chromasolv; Sigma-
Aldrich, UK) using both 488 nm and 561 nm laser lines. Calibration
measurements were collected using 10  10 s reads. FCS measure-
ments were performed using a range of VEGF165a-TMR concentra-
tions (0.25–10 nM) in Hanks Buffered Saline Solution (HBSS) with
or without 0.1% protease-free BSA (A7030; Sigma-Aldrich, UK).
Additional measurements were recorded in reducing conditions
consisting of HBSS/0.1% protease free BSA supplemented with
10 mM DTT, pre-incubated for 30 min at 37 C. Fluctuation mea-
surements were performed using 561 nm excitation light, with
emission collected through a long-pass LP580 filter. Time-
correlated measurements were recorded for up to 120 min with
laser power set to 20% (AOTF set to 10; equivalent to 0.39 kW/
cm2), measuring 2  10 s consecutive reads per well. Autocorrela-
tion analysis was performed using Zen2010 software (Zeiss, Ger-
many), with all data fitted to a single one-component, free 3D
Brownian diffusion model, including a pre-exponential for triple
state of the fluorophore.
2.10. NFAT luciferase reporter gene assay
NFAT luciferase reporter gene activity was monitored in a
HEK293T ReLuc2P (Promega Corporation, USA) suspension cell line
stably expressing VEGFR2 as described previously [10].
2.11. NFAT luciferase reporter gene assay in NLuc VEGFR2 cells
HEK293T NLuc VEGFR2 cells were seeded 48 h prior to assay
onto poly-D-lysine (0.1 mgmL1) coated white sided 96 well
plates (655089; Greiner Bio-One, UK) at a density of 25,000 cells/
well. Medium was removed and replaced with 100 ll serum freeg protease digestion of VEGF165a or VEGF165a-TMR. In (a) the labeling efficiency of
d proteolytic peptides in the labeled and unlabeled samples that were digested with
mass of the labeled peptides containing the N-terminal cysteine confirmed a mass
at a single charge assuming the peptide takes up a single proton. Mono-isotopic mass
ntion Time
n)
Protease Peak
Area
Protease
sample
% %
labeled
Trypsin/
LysC
1.04E+06 labeled 0.1 99.9
Trypsin/
LysC
1.20E+09 unlabeled 100
5 LysC 1.17E+08 labeled 0.9 99.1
LysC 1.25E+10 unlabeled 100
9 GluC 1.88E+07 labeled 1.3 98.7
7 GluC 1.42E+09 unlabeled 100
ass of un-labeled peptide
M+H]* (B)
Mass
difference (A–
B)
Retention Time (min)
(labeled)
Protease
008.86 817.28 23 Trypsin/
LysC
992.87 817.27 24.4 LysC
50.31 817.28 35.3 GluC
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assay, incubation medium was replaced with serum free
DMEM/0.1% protease free BSA (vehicle). Where appropriate, cells
were preincubated for 30 min with different concentrations of
RTKIs. Ligands were added in 10 ll to quadruplicate wells, and
plates incubated for 5 h at 37 C/5% CO2. Assay medium was then
removed and replaced with 50 ll vehicle per well. 50 ll of ONE-
GloTM Luciferase assay reagent (E6120; Promega Corporation,
USA) was then added to each well and luminescence measured
using a TopCount platereader (Perkin Elmer, UK).
2.12. NanoBRET ligand binding
HEK293T NLuc-VEGFR2 cells were seeded 24 h prior to assay
onto white sided poly-D-lysine coated 96 well plates at a density
of 40,000 cells/well. On the day of the assay, medium was replaced
with 50 ll per well HBSS/0.1% protease free BSA. Where appropri-
ate, RTKIs were added 30 min prior to agonist. For competition
experiments, a fixed concentration of fluorescent VEGF165a-TMR
was added simultaneously with competing unlabeled VEGF iso-
forms to triplicate wells for the time specified (10, 30 or 60 min)
and plates co-incubated at 37 C in the dark. For saturation exper-
iments a range of concentrations of VEGF165a-TMR were added in
the presence or absence of a competing concentration (30 nM) of
unlabeled VEGF165a and incubated for 60 min at 37 C in the dark.
The NanoLuc substrate furimazine (N1130; Promega Corporation,
USA) was then added at a final concentration of 10 lM. In time-
course experiments, VEGF165a-TMR (2, 10 or 20 nM) was added
to duplicate wells and incubated for 1 to 120 min before 10 lM
furimazine was added. For all experiments, sequential recordings
were performed at room temperature using a PHERAstar FS plate
reader (BMG Labtech, Germany) using 460 nm (80 nm bandpass;
donor NanoLuc emission) and >610 nm longpass filters (acceptor
emission). Raw BRET ratios were calculated from the ratio of accep-
tor to donor emission values. For real-time ligand association
kinetics experiments, cells were incubated with vehicle for
30 min at 37 C. Furimazine (10 lM) was then added and plates
equilibrated at 37 C in the PHERAstar FS plate reader for 5 min.
The required concentration of VEGF165a-TMR was then added to
the appropriate wells, and the plate then immediately returned
to the PHERAstar and luminescence and fluorescence readings
taken every 30 s for 16 min or 120 min at 37 C.
2.13. Measurement of VEGF165a-TMR internalization and VEGFR2
activation status using a widefield platereader
HEK293T NLuc-VEGFR2 cells were seeded 24 h prior to assay
onto poly-D-lysine coated black sided 96 well plates (655090; Grei-
ner Bio-One, UK) at a density of 30,000 cells/well. On the day of the
assay, medium was replaced with 100 ll per well serum free
DMEM/0.1% protease free BSA. Cells were incubated with increas-
ing concentrations of VEGF165a-TMR in triplicate wells for 60 min.
For competition experiments, VEGF165a-TMR (3 nM) was added
simultaneously with increasing concentrations of unlabeled
VEGF165a for 60 min. At the end of the incubation period, cells were
washed using PBS and fixed using 3% paraformaldehyde (Sigma-
Aldrich, UK)/PBS for 10 min at room temperature. Nuclei were then
stained using bisBenzimide H 33342 trihydrochloride (2 lg/ml in
PBS; Sigma-Aldrich, UK). Cells were imaged using a IX MDC Micro
widefield platereader (Molecular Devices, USA) fitted with a 20
Plan Apochromat NA0.6 extra long working distance objective,
with 4 sites imaged per well using DAPI (H33342; 405 nm excita-
tion, 447/60 emission) and TRITC (VEGF165a-TMR; 560 nm excita-
tion, 607/34 nm emission) filter settings. To track the time course
of internalization of VEGF165a-TMR/VEGFR2 complexes and the
corresponding activation status of the VEGFR2 within these cells,Please cite this article in press as: L.E. Kilpatrick et al., Real-time analysis of the
tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes3 nM VEGF165a-TMR was added at set time points (reverse time-
course, 120–1 min) in serum free DMEM/0.1% BSA. Cells were then
fixed using 3% PFA/PBS for 15 min at room temperature, perme-
abilised using 0.025% Triton-X-100 in PBS (Sigma-Aldrich, UK)
and non specific fluorescence quenched using 3% BSA/1% glycine
wash for 30 min at room temperature. Non-specific antibody bind-
ing was blocked at room temperature using 30 min incubation
with 10% chicken serum in PBS, prior to labeling with a rabbit anti-
body targeting either pY1175 (Cell Signalling No. 2478) or pY1214
(Cell Signalling No. 2477) residues of VEGFR2 (1:100 dilution in
10% chicken serum in PBS; overnight at 4 C). The next day cells
were labeled with a secondary antibody (chicken anti rabbit
AlexaFluor-488 (A-21441; ThermoFisher Scientific); 1:500 dilution
in 10% chicken serum/PBS; 60 min at room temperature). Cells
were then washed twice in PBS, nuclei stained using H33342
(2 mg/ml in PBS; 10 min at room temperature) and imaged using
a IX Micro widefield platereader using DAPI (H33342; 405 nm
excitation, 447/60 emission), FITC (anti pY1214 antibody;
488 nm excitation, 514 emission) and TRITC (VEGF165a-TMR;
560 nm excitation, 607/34 nm emission) filter settings.
To track the time course of VEGFR2-HaloTag internalization,
cells were seeded 24 h prior to assay onto poly-D-lysine coated
black sided, clear flat bottomed 96 well plates at a density of
30,000 cells/well. On the day of the assay, medium was replaced
with 50 ll per well 10% fetal calf serum/DMEM containing 1 lM
HaloTag-TMR cell permeant fluorescent ligand (15 min at
37 C/5% CO2; G8251, Promega Corporation, USA). Cells were then
washed 3 times with 80 ll 10% fetal calf serum/DMEM, prior to
incubation at 37 C/5% CO2 for 30 min. Medium was then removed
and replaced with 45 ll per well assay buffer (HBSS/0.1% BSA).
Unlabeled 3 nM VEGF165a was added at set time points (37 C).
Cells were then washed using PBS, fixed (3% PFA/PBS) and nuclei
stained using H33342 (2 mg/ml in PBS; 10 min at room tempera-
ture). Cells were imaged using a IX Micro widefield platereader
with 4 sites imaged per well using DAPI (H33342; 405 nm excita-
tion, 447/60 emission) and TRITC (HaloTag-TMR; 560 nm excita-
tion, 607/34 nm emission) filter settings.
Data were analysed using a granularity algorithm (MetaXpress
2.0, Molecular Devices, USA) with vesicles subjectively set in terms
of size (3–15 lm) and pixel grey levels in respect to negative and
positive plate controls. Data were pooled from 3 to 8 independent
experiments and expressed as number of vesicles on a per cell
basis.2.14. Confocal Zeiss LSM510 imaging
HEK293T NLuc-VEGFR2 cells were seeded 48 h prior to assay
onto poly-D-lysine coated 8 well plates (Nunc LabTek, Thermo
Fisher Scientific, UK) at a density of 20,000 cells/well. Medium
was replaced with serum free DMEM before cells were incubated
for a further 24 h at 37 C/5% CO2. On the day of the assay, cells
were washed three times with HBSS/0.1% protease free BSA (vehi-
cle). Receptor tyrosine kinase inhibitors were added at this point as
aliquots to the appropriate wells and cells incubated for 30 min at
37 C. Cells were then stimulated with 10 nM VEGF165a-TMR for
30 min at 37 C in the dark. Cells were imaged using a Zeiss
LSM510 fitted with a 63 Pan Apochromat oil objective (1.4NA)
using Argon 546 laser excitation, a long pass 540 filter and a pin-
hole diameter of 1 Airy unit. All images were taken at
1024  1024 pixels per frame with 8 averages.2.15. Structured Illumination microscopy
HEK293T cells were grown at a density of 200,000 cells on poly-
D-lysine coated 18  18 mm 1.5H coverglasses (474030-9000-000;binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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then transiently transfected with 3 lg per well of HaloTag VEGFR2
cDNA and grown for 24 h at 37 C/5% CO2. Cells were then incu-
bated with 0.5 lM HaloTag AF488 membrane impermeant ligand
(15 min at 37 C/5% CO2; G1002, Promega Corporation, USA) and
then washed three times with HBSS/0.1% BSA. For receptor tyrosine
kinase inhibitor experiments, cells were pretreated with vehicle or
1 lM cediranib (30 min at 37 C) and then stimulated with 10 nM
VEGF165a-TMR (30 min at 37 C). For timecourse experiments, cells
were treated with 3 nM VEGF165a-TMR for 5, 30, 60 or 120 min at
37 C. All cells were then fixed using 3% PFA/PBS (10 min at room
temperature), washed with PBS and mounted onto slides using
Prolong Gold antifade reagent (P10144; Thermo Fisher Scientific,
USA). TetraSpeckTM microspheres (0.1 lm; T7279, Thermo Fisher
Scientific, USA) were included in each experiment to allow X/Y/Z
channel alignment correction in image processing. Slides were
imaged using a Zeiss ELYRA PS.1 microscope using a Plan Apochro-
mat 63/1.4 oil DIC M27 objective with Zeiss ImmersolTM 518F
(30 C) oil (Zeiss, Germany). Multitrack imaging with HaloTag
VEGFR2 imaged using bandpass 495–550 plus longpass 750 filter
at 1% laser power with 150 ms exposure time (28 lm grating)
and VEGF165a-TMR with a bandpass 570–620 plus longpass 750 fil-
ter at 4% laser power with 50 ms exposure time (34 lm). All
images were acquired at 1024  1024 frame size over 5 rotations
as a Z stack of 30–40 slices. Images were manually processed with
consistent raw scaling between and within experiments. (Section-
ing of 100  83  93; Zen Black 2012, Zeiss, Germany).
2.16. HUVEC proliferation assay
Human umbilical vein endothelial cells (HUVECs; passage 4–6;
C0035C (newborn, single donor) Thermo Fisher Scientific, USA)
were grown to confluency in Medium 200 (Thermo Fisher Scien-
tific, USA) supplemented with large vessel endothelial supplement
(LVES 50; Thermo Fisher, USA) at 37 C/5% CO2. Cells were seeded
at 5000 cells per 100 ll/per well onto black, clear bottomed 96 well
plates (Grenier Bio-One, 655090) and left to grow at 37 C/5% CO2
for 24 h. The next day, the plating medium was replaced with
150 ll per well of Medium 200 with 0.1% serum for a further
24 h at 37 C/5% CO2. On day 3, cells were stimulated in triplicate
wells for 24 or 48 h at 37 C/5% CO2 with 3 nM or 30 nM VEGF165a
(R and D Systems) or VEGF165a-TMR in Medium 200/0.1% serum. At
the end of the incubation period, cells were washed with PBS
(100 ll/well), fixed using 3% PFA/PBS (20 min at room tempera-
ture) and nuclei stained using H33342 (2 mg/ml; 15 min at room
temperature). Nuclei were imaged at 4 sites per well using a IX
Micro widefield platereader (Molecular Devices, USA) fitted with
a 4 objective using a DAPI filter with 25 ms exposure time. Nuclei
were counted using a granularity algorithm (MetaXpress, Molecu-
lar Devices, USA). Data were normalised to show fold increases in
proliferation compared to vehicle treatment and expressed as
mean ± S.E.M.
2.17. Data analysis and statistical tests
Equilibrium binding: All data were analysed using Prism 6
(GraphPad; San Diego, CA, USA). NanoBRET competition experi-
ments were fitted as raw BRET ratios using non-linear least squares
regression (variable slope) with no constraints used. Saturation
curves were fitted simultaneously for total (VEGF165a-TMR alone)
and non-specific binding (top concentration of competing VEGF165a
alone) using both one and two site fits. Background and
non-specific binding parameters were shared across all data sets.
All saturations fitted preferentially to a one site fit using the
equation:Please cite this article in press as: L.E. Kilpatrick et al., Real-time analysis of the
tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes,Total binding ¼ BMAXx½B½B þ KD þMx½B þ C
where Bmax is the maximal specific binding, [B] the concentration of
fluorescent ligand (nM), KD the equilibrium dissociation constant
(nM), M the slope of the non specific binding component and C
the y axis intercept.
Binding affinities (Ki) of the unlabeled ligands were calculated
using the Cheng-Prusoff equation:
Ki ¼ IC50
1þ ½LKD
where [L] is the concentration of fluorescent ligand used (nM). KD
values (nM) were derived from saturation binding curves. IC50 is
the molar ligand concentration that will inhibit 50% of the specific
binding of the fluorescent ligand concentration [L] and was calcu-
lated using the equation:
% specific VEGF binding ¼ 100 IC50½A þ IC50
where [A] is the concentration of competing drug used.
Linear regression analysis was also performed on the relation-
ship between IC50 and [VEGF165a-TMR] using a variant of the
Cheng-Prusoff equation:
IC50 ¼ ð½VEGF165a TMR  Ki  KDÞ þ Ki
Association kinetics: Fluorescent ligand binding association
kinetic data were fitted to the following mono exponential associ-
ation function:
Y ¼ Ymax  ð1 ekobs tÞ
Ymax equals the level of specific binding at infinite time, t is the
time of incubation and kobs is the rate constant for the observed
rate of association.
To evaluate whether the data were compatible with a simple
mass-action equilibrium interaction with a single non-interaction
binding site, the kobs values obtained were compared at different
fluorescent ligand concentrations by investigating the linearity of
the relationship between them according to the expression:
kobs ¼ kon  ½L þ koff
where koff is the dissociation rate constant of the ligand in min–1
and kon is the association rate constant in M–1 min–1.
Kinetically determined KD values were calculated from these
kinetic parameters using the following equation:
KD ¼ koffkon
Concentration response course and time course data obtained from
automated imaging: For VEGF165a-TMR concentration response
curves of internalization of ligand/VEGFR2 complexes, data were
expressed as a percentage of responses obtained using 30 nM
VEGF165a-TMR (100%) or vehicle (0%). Data were fitted using
non-linear least squares regression (variable slope) using Graph-
Pad Prism. All data were expressed as mean ± S.E.M and pooled
from 8 independent experiments.
For 120 min time course data of VEGF165a-TMR internalization,
VEGFR2 activation (measured by anti p1175 or pY1214 labeling) or
VEGFR2-Halo internalization, data were normalised as a percent-
age of peak responses measured at 20 min stimulation (100%) or
with no agonist stimulation (0%) respectively. Data for VEGF165a-
TMR internalization were fitted to a mono exponential association
function:
Y ¼ Ymax  ð1 ekobs tÞbinding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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sured at 120 min, t is the time of stimulation and kobs is the rate
constant for the observed internalization.
All data were expressed as mean ± S.E.M and pooled from 4/5
independent experiments.
NFAT reporter genes: All data obtained from the NFAT luciferase
reporter gene assays were normalised to 10 nM VEGF165a
responses and fitted with non linear regression using the equation
as described previously [10].
Statistical analysis used unpaired t-test or ANOVA as appropri-
ate (P < 0.05). The n values in the text show the number of separate
repeat experiments.
HUVEC proliferation assays: All data were expressed as percent-
age fold increases in cell count following VEGF165a or VEGF165a-
TMR treatment when normalised to vehicle treatment alone
(100%). All data were expressed as mean ± S.E.M. Statistical analy-
sis using one way ANOVA was performed to compare vehicle with
ligand treatments (P < 0.001). The n values in the text show the
number of separate repeat experiments.Fig. 1. Synthesis and characterisation of purified VEGF165a-TMR. (a) Synthetic strategy fo
VEGF165a-TMR (Eex = 532 nm; Eem = 580 nm) in the presence or absence of 100 mM DT
albumin (0.1% BSA) and 10 mM DTT on VEGF165a-TMR concentrations measured using flu
and expressed as mean ± SEM. (d) Stimulation of NFAT luciferase production by HEK293T
prepared identically to the fluorescent analogue (open circles) or fluorescent VEGF165a-TM
which quadruplicate determinations were made. Data are expressed as a percentage of th
(e) Effect of VEGF165a and VEGFR165a-TMR on proliferation of human umbilical endoth
30 nM) for 24 or 48 h, HUVECs were fixed using 3% PFA/PBS and the nuclei stained using
magnification and nuclei were counted using a granularity algorithm (MetaXpress, Mo
vehicle treatment (mean ± S.E.M) and are pooled from 5 individual experiments. One way
compared to vehicle only for both 24 and 48 h treatments (***P < 0.0002; ****P < 0.0001)
referred to the web version of this article.)
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3.1. Synthesis of an active fluorescent variant of the VEGF165a
homodimer labeled on a single N-terminal cysteine
Synthesis and purification of a fluorescent variant of VEGF165a
labeled on a single amino acid was achieved as depicted in Fig. 1a.
Briefly, VEGF165a was genetically fused to an N terminal HaloTag
via a short amino acid linker containing a modified TEV recognition
site (EDLYFQC), which upon proteolytic cleavage releases VEGF165a
with an N terminal cysteine residue (cys-VEGF165a). The secreted
fusion protein expressed in HEK293T cells was covalently captured
onto HaloLink beads [33]. Cys-VEGF165a was released from the
beads by proteolytic cleavage using HaloTEV protease, while Halo-
Tag and HaloTEV remained permanently attached to the beads
eliminating the need for post cleavage removal. Proteolytic cleav-
age in the presence of TMR fluorophore coupled to 2-
cyanobenzothiazole (6-TMR-PEG-CBT) [31] enabled site specific
labeling of the released cys-VEGF165a via condensation of 6-TMR-r purification and labeling of VEGF165a-TMR. (b) Fluorescent SDS-PAGE analysis (of
T and with or without deglycosylation by PNGase. (c) Influence of bovine serum
orescence correlation spectroscopy (FCS). Data are from 3 independent experiments
cells stably expressing VEGFR2 by VEGF165a (R&D Systems; closed circles), VEGF165a
R (red circles). Values represent mean ± SEM from 4 independent experiments from
e response to 10 nM VEGF165a (R&D Systems) obtained in each separate experiment.
elial cells (HUVECs). Following stimulation with VEGF165a or VEGF165a-TMR (3 or
H33342 (2 mg/ml). Cells were imaged using a IX Micro widefield platereader at 4
lecular Devices). Data are presented as fold increases in proliferation compared to
ANOVA was used to determine the statistical significance of ligand treatment when
. (For interpretation of the references to colour in this figure legend, the reader is
binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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tion and labeling reaction were performed in a physiological buffer
under reducing conditions (100 mM tris(2-carboxyethyl)phosphine;
TCEP). The purified and labeled VEGF165a (VEGF165a-TMR) was col-
lected and dialyzed to allow final formation of the di-sulphide
linked anti-parallel VEGF165a homodimer under non-reducing
conditions.
Fluorescent SDS-PAGE analysis of the purified VEGF165a-TMR in
the presence or absence of 100 mM dithiothreitol (DTT) confirmed
that, in non-reducing conditions, VEGF165a-TMR was largely pre-
sent as a homodimer (Fig. 1b). Deglycosylation by PNGase pro-
vided evidence that the purified VEGF165a-TMR was glycosylated
(Fig. 1b). Labeling efficiency and specificity of the VEGF165a pro-
tomer with 6-TMR-PEG-CBT was determined by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) analysis
of labeled and unlabeled VEGF165a digested with multiple pro-
teases. This analysis indicated highly efficient and selective label-
ing of the N terminal cysteine residue (Fig. 2 and Table 1). 6-
TMR-PEG-CBT modification was identified exclusively on the N-
terminal cysteine residue at >98% labeling efficiency. We did not
observe non-specific labeling of any of the other 16 cysteine resi-
dues present in the VEGF165a protomer.
Using an NFAT reporter gene assay [10], we compared the ago-
nist activity of VEGF165a-TMR to non-fluorescent VEGF165a (puri-
fied in an identical manner to VEGF165a-TMR) and VEGF165a
obtained from a commercial source (R&D systems) in cells express-
ing the wild-type VEGFR2 receptor (pEC50 values were 9.78 ± 0.07,
9.72 ± 0.09 and 10.14 ± 0.07; n = 4 in each case). Our results indi-
cated that the two VEGF165a proteins exhibited small differences
in their potencies that may be related to the small modificationFig. 2. LC-MS/MS analysis of VEGF165a-TMR digested with multiple proteases. (a) Peptide
terminal cysteine is marked in red. None of the other 16 residues presented in the VEGF1
spectra using the Mascot search engine (Matrix Science Inc, Boston, USA) against a human
analysis of the peptide containing the N terminal cysteine (CDNAPMAEGGGQNHHEVVK
digested with LysC protease. Retention times and mono-isotopic masses are given in Tab
referred to the web version of this article.)
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of VEGF165a and VEGF165a-TMR purified in the same manner, how-
ever, indicated that they had identical potencies (Fig. 1d). VEGF165a
and VEGF165a-TMR also were able to stimulate the proliferation of
HUVECs to a similar extent (Fig. 1e).
3.2. VEGF165a-TMR exists as a homodimer in physiological solutions
To verify that VEGF165a-TMR existed as a homodimer in physi-
ological solutions, we undertook fluorescence correlation spec-
troscopy (FCS) analysis of the fluorescent ligand in solution
(Fig. 1c). This is a single molecule approach that allows the number
of fluorescence particles (and hence concentration) and their diffu-
sion coefficients to be measured [32,35]. Experiments performed in
Hank’s buffered saline solution (HBSS) in the presence of 0.1%
protease-free bovine serum albumin (BSA) maintained a constant
concentration of VEGF165a-TMR in solution for at least 1 h (data
not shown). The final concentrations obtained in solution were
very similar to the concentrations calculated for an antiparallel
dimer (Fig. 1c). The slope of the linear regression in Fig. 1c in the
presence of 0.1% BSA was 0.81 (R2 = 0.87; 95% confidence limits
0.71–0.90). In the absence of BSA, however, the free concentrations
of VEGF165a-TMR were markedly reduced (slope = 0.20; R2 = 0.84;
95% confidence limits 0.25–0.33; Fig. 1c). In the presence of
10 mM DTT, there was a twofold increase in the number of fluores-
cence particles at each concentration (slope = 1.62; R2 = 0.98; 95%
confidence limits 1.54–1.69; Fig. 1c). These data are consistent
with the presence of an antiparallel VEGF165a-TMR dimer in phys-
iological solution, labeled on each protomer with a single fluo-
rophore in non-reducing conditions.coverage achieved by digestion with LysC, GluC and Trypsin/LysC proteases. The N
65a protomer were labeled. Protein identity was confirmed by searching the MS/MS
database (SwissProt). The highest scoring hit was the VEGF sequence. (b) LC-MS/MS
) derived from VEGF165a and VEGF165a- that were purified in the same manner and
le 1. (For interpretation of the references to colour in this figure legend, the reader is
binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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Table 2
Summary of the binding properties and functional efficacies of VEGF ligand splice
variants in HEK293T NLuc VEGFR2 cells. Data are mean ± S.E.M of 5 separate
experiments. Each individual experiment was performed in triplicate. In the NFAT
reporter gene assays 10 nM VEGF165a was included in each experiment and maximal
responses are expressed relative to this. For the NanoBRET assays IC50 values were
converted to pKi values using the Cheng-Prusoff equation.
Ligand NanoBRET NFAT Luciferase reporter gene assay
pKi pEC50 % Maximum response
(VEGF165a = 100%)
VEGF165a 9.81 ± 0.14 9.90 ± 0.06 100
VEGF165b 9.41 ± 0.12 9.38 ± 0.06 68.1 ± 5.7
VEGF189a 8.99 ± 0.09 9.51 ± 0.11 71.1 ± 3.6
VEGF145a 8.74 ± 0.14 9.25 ± 0.09 71.6 ± 3.9
VEGF121a 9.47 ± 0.07 9.13 ± 0.20 65.9 ± 8.8
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tagged VEGFR2
The use of BRET and a new bright luciferase (NanoLuc) provided
the means to monitor ligand-binding interactions between
VEGF165a-TMR and full length VEGFR2 in living cells, and in real
time. Human VEGFR2 was labeled on its N-terminus with NanoLuc
and expressed in HEK293T cells (NLuc-VEGFR2). A schematic of the
proposed interaction between an antiparallel VEGF165a-TMR and
Ig-like domains 2 and 3 of a VEGFR2 homodimer is shown in
Fig. 3a. Saturable binding of VEGF165a-TMR detected by BRET
(KD = 0.92 ± 0.10 nM; n = 5; 60 min incubation) was largely pre-
vented by 30 nM VEGF165a (Fig. 3b). At each concentration of
VEGF165a-TMR (0.1–3 nM), competitive inhibition of receptor-
specific binding could be achieved in the presence of increasing
concentrations of VEGF165a, yielding an apparent pKi of
9.81 ± 0.14 (assuming mass action kinetics; n = 5; Table 2; Fig. 3c).
Analysis of the linear relationship (R2 = 0.97; p < 0.001) between
IC50 and the concentration of VEGF165a-TMR, assuming a competi-
tive interaction, indicated that the Ki value of VEGF165a was
0.22 nM and the KD (for VEGF165a-TMR) was 0.85 nM (Fig. 3d).3.4. Inhibition of VEGF165a-TMR binding by VEGF-A isoforms
In addition to VEGF165a, a number of other isoforms of VEGF-A
were investigated as inhibitors of VEGF165a-TMR binding to
VEGFR2 (Fig. 4). VEGF189a, VEGF165b, VEGF145a and VEGF121a were
all potent inhibitors of binding (Fig. 4; Table 2). The pKi values
obtained for each isoform reconciled with the pEC50 valuesFig. 3. Binding characteristics of VEGF165a-TMR to VEGFR2 in HEK293T cells. (a) Schem
terminal NanoLuc tagged VEGFR2 (NLuc-VEGFR2). (b) Saturation binding of increasing
(30 nM; to define non-specific binding). Data are expressed as raw BRET ratios. VEGF165
triplicate wells and incubated for 60 min at 37 C. Values represent mean ± S.E.M of five
shown in (c). Where not shown, the error bars are within the size of the symbol. (c) Inh
increasing concentrations of unlabeled VEGF165a. VEGF165a-TMR (0.1–3 nM) and unlabe
represent mean ± S.E.M of five independent experiments. Bars represent the binding of
competing unlabeled VEGF165a. The open bar shows the BRET ratio obtained in the absen
p < 0.001) of the relationship between IC50 value determined in (c) and the concentrati
VEGF165a (0.22 nM) and the slope (0.19) represents the ratio Ki/KD yielding a value of 0
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line (Table 2).
3.5. Association kinetics of VEGF165a-TMR binding to NLuc-VEGFR2
The ability to directly monitor in real time the binding of
VEGF165a-TMR to NLuc-VEGFR2 in living cells provided an oppor-
tunity to evaluate the kinetic parameters of ligand binding
(Fig. 5a). Kinetics analysis was undertaken for five different con-
centrations of VEGF165a-TMR (1–20 nM) and the data were fitted
to a simple association exponential model (Fig. 5a). An evaluation
of the kobs value obtained at each fluorescent ligand concentration
indicated that the linear relationship expected for a simple mass-
action equilibrium was not observed (Fig. 5b), and kobs was loweratic of the use of NanoBRET to investigate the binding of VEGF165a-TMR to an N
concentrations of VEGF165a-TMR in the presence or absence of unlabeled VEGF165a
a-TMR (0.1–3 nM) and unlabeled VEGF165a (30 nM) were added simultaneously to
independent experiments performed independently of displacement experiments
ibition of the binding of VEGF165a-TMR (0.1–3 nM) to NanoLuc-tagged VEGFR2 by
led VEGF165a were added simultaneously and incubated for 60 min at 37 C. Values
VEGF165a-TMR obtained at each fluorescent ligand concentration in the absence of
ce of either fluorescent or unlabeled ligand. (d) Linear regression analysis (R2 = 0.97;
on of VEGF165a-TMR. The y intercept provides an estimate for the Ki of competing
.85 nM for the KD of VEGF165a-TMR.
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Fig. 4. Inhibition of the binding of VEGF165a-TMR to NLuc-VEGFR2 by unlabeled VEGF isoforms. Fixed concentrations of VEGF165a-TMR (0.1–3 nM) were added
simultaneously with increasing concentrations of (a) VEGF165b, (b) VEGF121a, (c) VEGF145a and (d) VEGF189a, and incubated for 1 h at 37 C. Data represent mean ± S.E.M of 5
independent experiments, each performed in triplicate. Bars represent the binding of VEGF165a-TMR obtained at each fluorescent ligand concentration in the absence of
competing ligand. The open bar shows the BRET ratio obtained in the absence of VEGF165a-TMR.
L.E. Kilpatrick et al. / Biochemical Pharmacology xxx (2017) xxx–xxx 9than expected at high ligand concentrations. At the three lowest
concentrations of VEGF165a-TMR used, there was a linear relation-
ship that allowed estimation of kon (4.78  107 min1 M1) and koff
(0.11 min1) yielding a kinetic KD of 2.27 nM.
3.6. The effect of receptor tyrosine kinase inhibitors on the binding of
VEGF165a-TMR to VEGFR2
Receptor tyrosine kinases inhibitors (RTKIs) targeted at VEGFR2
have proved to be attractive approaches to cancer therapy [3]. Here
we have investigated whether they have an allosteric effect on the
binding of VEGF to its receptor. Initial studies evaluated the impact
of four RTKIs on the specific binding of 10 nM VEGF165a-TMR to
NLuc-VEGFR2 using BRET following 60 min incubation with
VEGF165a (Fig. 6a). Cediranib, pazopanib, sorafenib and vandetanib
all caused a concentration-dependent increase in the binding of
10 nM VEGF165a-TMR (maximal responses were 139.0 ± 4.4,
144.8 ± 3.5, 149.3 ± 3.2 and 152.8 ± 7.1% respectively, relative to
binding of VEGF165a-TMR alone; n = 4; Fig. 6a; Table 3). The EC50
values obtained for each RTKI for this increase in binding were sim-
ilar to the IC50 values obtained for these compounds from inhibi-
tion of the NFAT reporter gene response to 1 nM VEGF165a in the
same cells (Table 3). Analysis of the saturation binding curves for
VEGF165a-TMR binding to NLuc-VEGFR2, in the presence and
absence of 1 lM cediranib, (Fig. 6b) confirmed that this effect
was on BMAX and did not change the KD value of VEGF165a-TMR
(KD = 1.18 ± 0.56 nM and 1.14 ± 0.44 nM in the presence and
absence of 1 lM cediranib).
The availability of a red fluorescently tagged variant of VEGF165a
also provided an opportunity to evaluate the cellular location of
VEGF165a-TMR in living cells using fluorescence microscopy
(Fig. 7a). In the absence of RTKIs, VEGF165a-TMR (applied at
10 nM) was largely visible in intracellular vesicles after 30 minPlease cite this article in press as: L.E. Kilpatrick et al., Real-time analysis of the
tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes,incubation (Fig. 7a). However, it was striking that after a 30 min
pre-incubation period with cediranib, bright VEGF165a-TMR fluo-
rescence was largely localised to the cell membrane (Fig. 7a).
Structured illumination super resolution microscopy (SIM) to eval-
uate the co-localisation of HaloTag-VEGFR2 and VEGF165a-TMR
binding confirmed these observations (Fig. 7a). The time course
of the effect of cediranib on the binding of 2, 10 and 20 nM
VEGF165a-TMR is shown in Fig. 7b. Over incubation times > 20 min,
there was a reduction in the BRET signal that can be prevented by
cediranib (Fig. 7b). However, the ability of VEGF165a to compete
with VEGF165a-TMR binding was very similar at all time points
studied (Fig. 8) and yielded similar pKi values (Table 4).
3.7. Impact of VEGFR2 internalization and ligand dissociation within
intracellular endosomes
The real-time kinetics of ligand-binding to NLuc VEGFR2 over
longer incubation times are shown in Fig. 9a. Up to 2 h after addi-
tion of VEGF165a-TMR there was still a measurable BRET signal at
all concentrations of the fluorescent ligand indicating that some
of the VEGF165a-TMR and NLuc-tagged receptor are still in very
close proximity at these later incubation times (Fig. 9a). The ability
of RTKIs to inhibit both VEGFR2 internalization induced by high
concentrations of VEGF165a-TMR (Fig. 8a) and the reduction in
the NanoBRET signal (Fig. 8b) raises two possibilities: (1) the
reduction in BRET signal over long incubation times in the absence
of RTKIs is a consequence of the different local environment of
intracellular endosomes or (2) it is due to VEGF165a-TMR/VEGFR2
dissociation within the acidic and proteolytic environment of the
intracellular endosomes. Some insights into the mechanisms
underlying these observations are provided by a comparison of
the temporal profile of the NanoBRET signal (Fig. 9a) and the extent
of the appearance of phosphorylated active VEGFR2 (Y1214 orbinding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
Biochem. Pharmacol. (2017), http://dx.doi.org/10.1016/j.bcp.2017.04.006
Fig. 5. Ligand binding kinetics of VEGF165a-TMR to VEGFR2. (a) Time course of
VEGF165a-TMR binding to NLuc-VEGFR2. HEK293T cells expressing NLuc-VEGFR2
were treated with furimazine and the plate left to equilibrate for 5 min. Vehicle or
VEGF165a-TMR (1–20 nM; coloured symbols) was then added to the appropriate
wells, and measurements made every 30 s for 16 min at 37 C. Data represent
mean ± S.E.M from 5 independent experiments. Individual curves were fitted to a
simple exponential association model to obtain Kobs. (b) A plot of Kobs values
obtained in (a) with increasing concentrations of VEGF165a-TMR.
Fig. 6. Effect of receptor tyrosine kinase inhibitors (RTKIs) on VEGFR2 ligand binding. (a)
sorafenib or vandetanib prior to the addition of 10 nM VEGF165a-TMR for 60 min at 37
VEGF165a-TMR in the absence of inhibitor (V; filled bar). Data represent mean ± S.E.M fr
VEGF165a-TMR binding to NLuc-VEGFR2 in the absence (solid lines) or presence (dotte
independent experiments.
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tion of fluorescent VEGF165a-TMR (Fig. 9b). The profile of pY1214
or pY1175-VEGFR2 within intracellular vesicles essentially follows
that of the NanoBRET signal (Fig. 9b). In contrast, the appearance of
VEGF165a-TMR within intracellular vesicles lags the phosphoryla-
tion of VEGFR2 and is sustained for 2 h (Fig. 9b). The internaliza-
tion (t1/2 = 9.18 ± 0.71 min; 95% confidence limits = 6.93–11.41;
n = 4) of VEGF165a-TMR was concentration dependent
(pEC50 = 8.68 ± 0.03; n = 8) and inhibited by co-incubation with
VEGF165a (pIC50 9.68 ± 0.10, n = 6; for inhibition of the internaliza-
tion of 3 nM VEGF165a-TMR). To confirm the temporal profile of
total VEGFR2 internalization following stimulation with VEGF165a,
we also generated a stable cell line expressing VEGFR2 with a Halo-
Tag on its C-terminus. Stimulation of these cells with 3 nM
VEGF165a produced a rapid internalization of VEGFR2 into intracel-
lular vesicles that peaked between 10 and 20 min (Fig. 9c) and then
followed the same time course as the phosphorylated receptor
(Fig. 9b) and the VEGF165a-TMR ligand binding BRET signal
(Fig. 9a). Taken together, these data suggest that VEGFR2 is inter-
nalized by VEGF165a-TMR into intracellular endosomes where the
BRET signal is decreased over time as a consequence of the disso-
ciation of the fluorescent ligand from the internalized receptor.
Confocal microscopy of N-terminal HaloTag VEGFR2 under basal
conditions showed that a significant proportion was constitutively
internalized, with the remainder on the cell membrane (Fig. 10a).
Super-resolution SIM of the co-localisation of VEGF165a-TMR and
N-terminal HaloTag VEGFR2 showed that it was confined to the
cell membrane at early time points (5 min) after addition of the
fluorescent agonist and fully colocalised in intracellular vesicles
after 30 min (Fig. 10b). However, following longer incubation times
(120 min) this co-localisation is lost and free HaloTag VEGFR2
returned to the cell surface (Fig. 10b).4. Discussion
This study has provided for the first time quantitative informa-
tion on the real time binding of VEGF-A isoforms to full length
VEGFR2 in living cells. Analysis of the specific binding of VEGF165-
a-TMR to NLuc-VEGFR2 indicated an apparent KD value of 0.92 nM
that was very similar to the EC50 value obtained with this labeled
VEGF165a analogue in NFAT reporter gene assays. Furthermore,NLuc VEGFR2 cells were pre-treated for 30 min at 37 C with cediranib, pazopanib,
C. The bars represent cells stimulated with vehicle (B; open bar; basal) or 10 nM
om 4 independent experiments in which triplicate determinations were made. (b)
d lines; 30 min pre-incubation) of 1 lM cediranib. Data are mean ± S.E.M of four
binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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Fig. 7. Cellular location and time course of VEGF165a-TMR binding to NLuc-VEGFR2. (a) Confocal (upper panels) (Zeiss LSM 510) or (low panels) Structured Illumination
Microscopy (SIM) super resolution images of cells pre-treated with vehicle or 1 lM cediranib for 30 min at 37 C followed by stimulation with 10 nM VEGF165a-TMR for a
further 30 min at 37 C. Images are representative of 3 independent experiments. (b) Influence of incubation time on NanoBRET ligand-binding characteristics. Cells were pre-
treated with vehicle (solid lines) or 1 lM cediranib (dotted lines) for 30 min at 37 C, prior to stimulation with 2 nM, 10 nM or 20 nM VEGF165a-TMR over 120 min at 37 C.
Data (mean ± S.E.M) are expressed as a percentage of the BRET ratio obtained at 120 min with 20 nM VEGF165a-TMR from four independent experiments.
Fig. 8. Influence of incubation time on ligand binding competition experiments in the presence or absence of cediranib. HEK293T NLuc VEGFR2 cells were pretreated with
either (a) vehicle or (b) 1 lM cediranib for 30 min at 37 C prior to continued incubation in the presence of VEGF165a-TMR (0.5–3 nM) and various concentrations of VEGF165a
for 10, 30 or 60 min at 37 C. Data represent mean ± S.E.M from 3 to 4 independent experiments.
Table 3
Summary of the effect of RTKIs on 10 nM VEGF165a-TMR induced BRET ratios in HEK293T NLuc VEGFR2 cells. For NanoBRET binding assays cells were pretreated with a RTKI for
30 min prior to addition of 10 nM VEGF165a-TMR for a further 60 min. Data are expressed as mean ± SEM and the number of separate experiments is given in parentheses. Each
individual experiment was performed in triplicate. For NFAT reporter gene assays, cells were treated with each RTKI for 60 min prior to the addition of 1 nM VEGF165a for 5 h.
Inhibitor NanoBRET NFAT Luciferase
pEC50 % Increase in binding of 10 nM VEGF165a-TMR pIC50
Cediranib 8.52 ± 0.13 (4) 139.0 ± 2.0 (4) 9.78 ± 0.73 (6)
Pazopanib 7.70 ± 0.24 (4) 144.8 ± 3.5 (4) 8.55 ± 0.19 (5)
Sorafenib 7.38 ± 0.14 (4) 149.3 ± 3.2 (4) 7.77 ± 0.45 (6)
Vandetanib 5.84 ± 0.12 (4) 152.8 ± 7.1 (4) 6.26 ± 0.27 (5)
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Table 4
Summary of NanoBRET derived binding affinity measurements when VEGF165a-TMR
and VEGF165a are simultaneously co-incubated for set incubation times in the
presence or absence of cediranib. Values are mean ± SEM of 3–4 separate exper-
iments. pKi values determined from individual experiments summarised in Fig. 8.
Ligand incubation time (min) VEGF165a pKi
Plus 1 lM cediranib
10 8.93 ± 0.09 9.17 ± 0.04
30 8.99 ± 0.10 9.23 ± 0.06
60 9.28 ± 0.06 9.18 ± 0.06
Fig. 9. Internalization and activation status of VEGFR2 in response to VEGF165a. (a) Tim
prior to VEGF165a-TMR. (b) Time course of the internalization of VEGF165a-TMR (red cir
indicative of VEGFR2 activation) within the same cells. 3 nM VEGF165a-TMR was added
(0.025% Triton-X-100/PBS) and labeled with a rabbit antibody targeting pY1175 (purple
widefield platereader. Data are expressed as a percentage of the peak responses at 20 m
3 nM VEGF165a induced internalization of VEGFR2-HaloTag. Cells were labeled with 0
analysed and data expressed as described for (b). (For interpretation of the references to
Fig. 10. (a) Confocal imaging in HEK293T cells transiently expressing HaloTag VEGFR2. HE
at 37 C. All cells were imaged live using a Zeiss LSM Exciter and are representative imag
super resolution images of HEK293T cells transiently transfected with HaloTag VEGFR2 (g
at 37 C). Areas of colocalisation are shown in yellow and examples shown by the closed
by the open white arrow.
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a range of VEGF-A isoforms to be determined. These values were in
close agreement with the pEC50 values obtained in a functional
NFAT reporter gene assay in the same cells. Furthermore, the pKi
values for VEGF165a and VEGF165b were also similar to those deter-
mined with 125I-labeled VEGF165a [5,7] or by the operational model
of Black & Leff from functional NFAT responses [10].
Kinetic analysis of the binding of the antiparallel dimeric
VEGF165a-TMR to NLuc-VEGFR2 over the first 16 min (before sig-
nificant receptor internalization occurred) indicated that the data
fitted well to a simple association exponential. However, the kobse course of VEGF165a-TMR binding to NLuc-VEGFR2. Furimazine was added 5 mins
cles) and activated VEGFR2 (stained with antibodies targeting phosphate moieties
at set time points (1–120 min). Cells were fixed using 3% PFA/PBS, permeabilised
triangles) or pY1214 of VEGFR2 (black circles). Cells were imaged using a IX Micro
in and represent mean ± S.E.M from 3 independent experiments. (c) Timecourse of
.5 lM HaloTag-TMR fluorescent ligand as described under Methods. Images were
colour in this figure legend, the reader is referred to the web version of this article.)
K293T cells stably expressing HaloTag VEGFR2 were treated with vehicle for 30 min
es from 3 independent experiments. (b). Structured Illumination Microscopy (SIM)
reen) and treated for distinct time points with 3 nM VEGF165a (red; 5, 30 or 120 min
white arrow. Examples of non-localised intracellular HaloTag VEGFR2 are illustrated
binding of fluorescent VEGF165a to VEGFR2 in living cells: Effect of receptor
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from this analysis did not fit with the linear relationship expected
for a simple mass-action equilibrium with non-interacting binding
sites. However, at the three lowest concentrations of VEGF165a-
TMR used, there was a linear relationship that allowed a rough
estimation of kon (4.78  107 min1 M1) and koff (0.11 min1) to
be made yielding a kinetic KD (2.3 nM) that was very similar to
the value obtained from equilibrium determinations above.
Receptor tyrosine kinases inhibitors (RTKIs) targeted at VEGFR2
have proved to be attractive approaches to cancer therapy based
on their ability to reduce angiogenesis and/or lymphangiogenesis
[3]. Here we used the NanoBRET assay to evaluate whether RTKIs
had an allosteric effect on the direct binding of VEGF165a-TMR to
NLuc-VEGFR2 in living cells. Surprisingly, all four compounds stud-
ied increased the maximum binding (measured at 60 min) of
VEGF165a-TMR by 40–50% without altering its KD. However, a
noticeable feature of their action was that they largely prevented
the internalization of VEGFR2 induced by high concentrations of
VEGF165a-TMR. In the absence of RTKIs, the binding of 10 nM
VEGF165a-TMR appeared to be largely intracellular after 30 min
incubation.
This agonist-induced receptor internalization was time and
concentration dependent, and could be monitored in a quantitative
manner using high content imaging of the location of VEGF165a-
TMR, phosphorylated VEGFR2 (pY1214 and pY1175) or VEGFR2
attached to a C terminal HaloTag. It was noticeable that there
was a sustained BRET signal (between NLuc-VEGFR2 and VEGF165-
a-TMR) that lasted for up to 2 h, suggesting that some of the fluo-
rescent ligand and NLuc-VEGFR2 remain in close proximity within
endosomes [36]. There was, however, a noticeable decrease in this
BRET signal over longer incubation times at high concentrations of
VEGF165a-TMR, which could reflect the influence of the local acidic
environment of intracellular endosomes. However, the differential
time courses of the ligand-binding BRET signal, internalized active
phosphorylated VEGFR2 and the appearance of VEGF165a-TMR in
intracellular endosomes points to a different conclusion. The sim-
ilarity of the time courses for NanoBRET, pY1214 or pT1175
VEGFR2 and VEGFR2-HaloTag internalization suggests that this
reflects the appearance of agonist-occupied ‘active’ VEGFR2 in
intracellular endosomes. This taken alongside the highly localised
intracellular VEGF165a-TMR fluorescence at later time points sug-
gests that the ligand has dissociated from the receptor in the acidic
environment of the intracellular endosomes and allowed VEGFR2
to recycle back to the plasma membrane, consistent with previous
observations of the rapid constitutive recycling of VEGFR2 [37], or
be degraded within lysosomes [38]. This conclusion is supported
by SIM analysis of the subcellular co-localisation of HaloTag-
VEGFR2 and VEGF165a-TMR at different time points.
In summary, we have used novel protein chemistry to generate
a fluorescent variant of VEGF (VEGF165a-TMR) labeled on a single
cysteine within each protomer of the antiparallel VEGF homod-
imer. This has been used in conjunction with full length VEGFR2,
tagged with the bioluminescent protein NanoLuc, to undertake a
real time quantitative evaluation of VEGFR2 and binding character-
istics in living cells using bioluminescence energy transfer (BRET).
At longer incubation times, VEGFR2 is internalized by VEGF165a-
TMR into intracellular endosomes where the BRET signal is
decreased over time as a consequence of the dissociation of agonist
from the receptor and receptor recycling. This internalization can
be prevented by the receptor tyrosine kinase inhibitors (RTKIs)
cediranib, sorafenib, pazopanib or vandetanib. This new under-
standing of VEGFR2 ligand-receptor interactions should provide
new insights and opportunities for future drug discovery efforts
aimed at cancer angiogenesis.Please cite this article in press as: L.E. Kilpatrick et al., Real-time analysis of the
tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes,Author contributions
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